Uplisting it''s a possibility but Gerald has stated if necessary it will not take place lin the short term but later this year. First thing first. Market authorisation for Lympro first. Sounds logical to me. Certainly if the insurance companies give the green light their is a possibility the shareprice will rice that much that a R/S is not necessary for uplisting and it will be a lot easier to find the right partner if necessary!
Market Data 
Markets 
AI
